Drug Profile
PF 6755992
Alternative Names: PF-06755992Latest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Aug 2023 Discontinued - Preclinical for Cancer in USA (Parenteral)
- 28 Dec 2019 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 24 Nov 2015 Preclinical trials in Cancer in USA (Parenteral) before November 2015